Abbott Diagnostics will be attending Biomed 2011 and is interested in discussions with potential collaborators leading toward the development and commercialization of novel IA/CC biomarkers in all therapeutic areas:
o Evidence of clinical utility
o Well characterized antibody development
o Preferably, a developed ELISA format
o Workable, defendable, global IP position
Popularity: 53% [?]
NewPR – content development, technology, and social media strategies
90 Responses to “Abbott Diagnostics @ Biomed 2011”